BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant

BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the delta variant

Bibliographic Details
Main Authors:	Sheikh, A, Robertson, C, Taylor, B
Format:	Journal article
Language:	English
Published:	Massachusetts Medical Society 2021

Similar Items

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
by: Hermosilla, E, et al.
Published: (2022)

Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
by: Simpson, CR, et al.
Published: (2022)

Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50
by: Xie, J, et al.
Published: (2022)

Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
by: Chua, Jia Xin, et al.
Published: (2022)

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland
by: Simpson, CR, et al.
Published: (2021)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
by: Ogbe, A, et al.
Published: (2022)

ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply
by: Madhi, SA, et al.
Published: (2021)

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
by: Wei, J, et al.
Published: (2022)

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
by: Agrawal, U, et al.
Published: (2021)

Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant
by: Madhi, SA, et al.
Published: (2021)

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - author's reply
by: Voysey, M, et al.
Published: (2021)

Kinetics of neutralizing antibodies against Omicron variant in Vietnamese healthcare workers after primary immunization with ChAdOx1-S and booster immunization with BNT162b2
by: Chau, NVV, et al.
Published: (2022)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
by: Zhang, C, et al.
Published: (2023)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply
by: Voysey, M, et al.
Published: (2020)

Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: a case report
by: Tan, Wee Yong, et al.
Published: (2021)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
by: Hillson, K, et al.
Published: (2021)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
by: Marchevsky, NG, et al.
Published: (2022)

Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine
by: Aguas, R, et al.
Published: (2021)

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial
by: Liu, X, et al.
Published: (2022)

Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort
by: Joy, M, et al.
Published: (2023)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
by: Moreira Folegatti, P
Published: (2021)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
by: Clemens, SAC, et al.
Published: (2021)

Central retinal vein occlusion post ChAdOx1 nCoV-19 vaccination - can it be explained by the two-hit hypothesis?
by: Parakh, Shweta, et al.
Published: (2023)

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
by: Kaplonek, P, et al.
Published: (2023)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
by: Watanabe, Y, et al.
Published: (2021)

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
by: Lambe, T, et al.
Published: (2021)

Plasmacytoid dendritic cells are central regulators of the humoral ChAdOx1 nCoV-19 vaccine response in a human tonsil organoid model
by: Provine, N, et al.
Published: (2024)

First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales
by: Kerr, S, et al.
Published: (2022)

Waning of first and second dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
by: Kerr, S, et al.
Published: (2022)

Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil
by: Clemens, SAC, et al.
Published: (2022)

Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
by: Stedman, A, et al.
Published: (2019)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
by: Folegatti, P, et al.
Published: (2019)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial
by: Ewer, K, et al.
Published: (2020)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
by: Barrett, J, et al.
Published: (2020)

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
by: Hamaluba, M, et al.
Published: (2023)

A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults
by: Iwata, S, et al.
Published: (2024)

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.
by: Swanson, PA, et al.
Published: (2021)

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
by: Wajja, A, et al.
Published: (2024)

Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels
by: Alharbi, N, et al.
Published: (2019)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
by: Sharpe, HR, et al.
Published: (2022)